Keyphrases
Interleukin-4 (IL-4)
100%
Interleukin-13 (IL-13)
100%
Molecular Targets
100%
Severe Asthma
100%
Interleukin-5 (IL-5)
100%
Biologic Therapy
100%
Monoclonal Antibody
50%
Clinical Benefit
50%
Airway
25%
Therapeutic Potential
25%
Clinical Features
25%
Asthmatic
25%
Eosinophils
25%
Chronic Inflammatory Diseases
25%
Signaling Cascades
25%
Asthma Phenotypes
25%
Blockage
25%
Complex Interplay
25%
Cytokine Receptor
25%
Head-to-head Trials
25%
Phase II Trial
25%
Cytokine Pathways
25%
Eosinophil Count
25%
Biological Mechanisms
25%
Antibody Targeting
25%
Severe Atopic Dermatitis
25%
Therapeutic Monoclonal Antibody
25%
Interleukin-4 Receptor
25%
Biomarker Characteristics
25%
Phenotype Selection
25%
Severe Eosinophilic Asthma
25%
Th2 Inflammatory Response
25%
Pharmacology, Toxicology and Pharmaceutical Science
Molecular Target
100%
Asthma
100%
Interleukin 4
100%
Interleukin 5
100%
Interleukin 13
100%
Monoclonal Antibody
75%
Cytokine
75%
Biological Product
75%
Disease
25%
Biological Marker
25%
Clinical Feature
25%
Inflammation
25%
Atopic Dermatitis
25%
Cytokine Receptor
25%
Interleukin 4 Receptor
25%
Immunology and Microbiology
Interleukin 13
100%
Interleukin 4
100%
Severe Asthma
100%
Interleukin 5
100%
Cytokine
75%
Biological Product
75%
Monoclonal Antibody
50%
Asthma
50%
Inflammation Response
25%
Eosinophil
25%
Inflammatory Disorder
25%
Cytokine Receptor
25%
Eosinophil Count
25%
Atopic Dermatitis
25%
Interleukin-4 Receptor
25%
Monoclonal Antibody Therapy
25%